Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Three-Compartment Open Model01:06

Three-Compartment Open Model

1.1K
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
1.1K
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

335
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
335

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sintering Method-Dependent Hydroxyapatite Coatings Drive Enhanced Gingival Fibroblast Behavior on Titanium Implant Surfaces.

Materials (Basel, Switzerland)·2026
Same author

Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials.

International journal of radiation oncology, biology, physics·2026
Same author

Proton versus photon therapy for oropharyngeal cancer - Authors' reply.

Lancet (London, England)·2026
Same author

MDASI-HN Symptom Profiling for Early-Risk Stratification of Hypoglossal Neuropathy in Survivors of Oropharyngeal Cancer.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Advancing Particle Therapy to Improve Cancer Care: Report on "2nd World Forum on Particle Therapy".

International journal of particle therapy·2026
Same author

Introduction from the Guest Editors.

Cancer journal (Sudbury, Mass.)·2026

Related Experiment Video

Updated: Mar 27, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Normal Tissue Complication Probability Modeling for Proton Therapy.

Mei Chen1, Zhongxing Liao1, Steven J Frank2

  • 1Departments of Thoracic Radiation Oncology.

Cancer Journal (Sudbury, Mass.)
|March 25, 2026
PubMed
Summary

Accurate normal tissue complication probability (NTCP) models are crucial for proton therapy. This review highlights the need for proton-specific models and better management of prediction uncertainty in clinical decision-making.

Keywords:
Proton therapydose-response relationshipmodel uncertaintynormal tissue complication probabilityrelative biological effectiveness

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.3K

Related Experiment Videos

Last Updated: Mar 27, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.3K

Area of Science:

  • Medical Physics
  • Radiation Oncology
  • Clinical Decision Support

Background:

  • Accurate normal tissue complication probability (NTCP) models are essential for optimizing proton therapy planning and patient selection.
  • Proton therapy's unique dose-response characteristics necessitate specialized toxicity models beyond those derived from photon therapy.

Purpose of the Study:

  • To review the challenges in developing accurate proton-specific NTCP models.
  • To examine the management of NTCP prediction uncertainty for reliable clinical decision-making in proton therapy.

Main Methods:

  • Literature review of existing NTCP models and their applicability to proton therapy.
  • Analysis of the endpoint-dependency of NTCP model accuracy.
  • Assessment of clinical evidence for incorporating variable relative biological effectiveness.
  • Evaluation of the attention paid to prediction uncertainty in clinical decision frameworks.

Main Results:

  • Photon-derived NTCP models are not universally applicable to proton therapy, with accuracy being endpoint-dependent.
  • Clinical evidence supporting the update of NTCP models with variable relative biological effectiveness is limited due to heterogeneity and inconsistent findings.
  • The impact of NTCP prediction uncertainty on patient selection has been inadequately addressed.

Conclusions:

  • Proton-specific NTCP models are required for certain toxicity endpoints.
  • Further research is needed to develop a robust framework for NTCP-guided patient selection that accounts for both model accuracy and prediction confidence.
  • Addressing model uncertainty is critical for reliable clinical decision-making in proton therapy.